REFERENCE
1. Bernard J, Weil M, Jacquillat C. Treatment of acute lymphoblastic leukemia. N Engl J Med . 2006;354(2):1-11. doi:10.1056/NEJMRA052603
2. Sallan SE, Hitchcock-Bryan S, Gelber R, Cassady JR, Frei E, Nathan DG. Influence of Intensive Asparaginase in the Treatment of Childhood Non-T-Cell Acute Lymphoblastic Leukemia. Cancer Res . 1983;43(11).
3. Clavell LA, Gelber RD, Cohen HJ, et al. Four-Agent Induction and Intensive Asparaginase Therapy for Treatment of Childhood Acute Lymphoblastic Leukemia. N Engl J Med . 1986;315(11):657-663. doi:10.1056/nejm198609113151101
4. Asselin BL, Whitin JC, Coppola DJ, Rupp IP, Sallan SE, Cohen HJ. Comparative pharmacokinetic studies of three asparaginase preparations.J Clin Oncol . 1993;11(9):1780-1786. doi:10.1200/JCO.1993.11.9.1780
5. Lanvers-Kaminsky C. Asparaginase pharmacology: challenges still to be faced. Cancer Chemother Pharmacol 2017 793 . 2017;79(3):439-450. doi:10.1007/S00280-016-3236-Y
6. Avramis VI, Sencer S, Periclou AP, et al. A randomized comparison of native Escherichia coli asparaginase and polyethylene glycol conjugated asparaginase for treatment of children with newly diagnosed standard-risk acute lymphoblastic leukemia: A Children’s Cancer Group study. Blood . 2002;99(6):1986-1994. doi:10.1182/blood.V99.6.1986
7. Silverman LB, Supko JG, Stevenson KE, et al. Intravenous PEG-asparaginase during remission induction in children and adolescents with newly diagnosed acute lymphoblastic leukemia. Blood . 2010;115(7):1351-1353. doi:10.1182/BLOOD-2009-09-245951
8. Rizzari C, Asselin B. Asparaginase pharmacokinetics and implications of therapeutic drug monitoring. Leuk Lymphoma . 2015;56(8):2273-2280. doi:10.3109/10428194.2014.1003056
9. Brigitha LJ, Pieters R, van der Sluis IM. How much asparaginase is needed for optimal outcome in childhood acute lymphoblastic leukaemia? A systematic review. Eur J Cancer . 2021;157:238-249. doi:10.1016/J.EJCA.2021.08.025
10. Vora A, Wade R, Mitchell C, Goulden N, Richards S. Efficacy and Toxicity of Pegylated Asparaginase in the Treatment of Children and Young Adults with Acute Lymphoblastic Leukaemia: Results of the United Kingdom Medical Research Council (MRC) Trial UKALL 2003. Blood . 2008;112(11):909-909. doi:10.1182/BLOOD.V112.11.909.909
11. Dinndorf PA, Gootenberg J, Cohen MH, Keegan P, Pazdur R. FDA Drug Approval Summary: Pegaspargase (Oncaspar) for the First-Line Treatment of Children with Acute Lymphoblastic Leukemia (ALL). doi:10.1634/theoncologist.12-8-991
12. Place AE, Stevenson KE, Vrooman LM, et al. Intravenous pegylated asparaginase versus intramuscular native Escherichia coli l-asparaginase in newly diagnosed childhood acute lymphoblastic leukaemia (DFCI 05-001): a randomised, open-label phase 3 trial. Lancet Oncol . 2015;16(16):1677-1690. doi:10.1016/S1470-2045(15)00363-0
13. Cooper SL, Young DJ, Bowen CJ, Arwood NM, Poggi SG, Brown PA. Universal premedication and therapeutic drug monitoring for asparaginase-based therapy prevents infusion-associated acute adverse events and drug substitutions. Pediatr Blood Cancer . 2019;66(8):e27797. doi:10.1002/PBC.27797
14. Kloos RQH, Pieters R, Jumelet FMV, De Groot-Kruseman HA, Van Den Bos C, Van Der Sluis IM. Individualized asparaginase dosing in childhood acute lymphoblastic leukemia. J Clin Oncol . 2020;38(7):715-724. doi:10.1200/JCO.19.02292
15. Sankaran H, Sengupta S, Purohit V, et al. A comparison of asparaginase activity in generic formulations of E.coli derived L- asparaginase: In-vitro study and retrospective analysis of asparaginase monitoring in pediatric patients with leukemia. Br J Clin Pharmacol . 2020;86(6):1081-1088. doi:10.1111/bcp.14216
16. Sidhu J, Gogoi MP, Agarwal P, et al. Unsatisfactory quality of E. coli asparaginase biogenerics in India: Implications for clinical outcomes in acute lymphoblastic leukaemia. Pediatr Blood Cancer . 2021;68(11). doi:10.1002/PBC.29046
17. Vyas C, Jain S, Kapoor G, Mehta A, Takkar Chugh P. Experience with generic pegylated L-asparaginase in children with acute lymphoblastic leukemia and monitoring of serum asparaginase activity. Pediatr Hematol Oncol . 2018;35(5-6):331-340. doi:10.1080/08880018.2018.1538277
18. Hijiya N, Van Der Sluis IM. Asparaginase-associated toxicity in children with acute lymphoblastic leukemia. Leuk Lymphoma . 2016;57(4):748-757. doi:10.3109/10428194.2015.1101098
19. Gupta S, Wang C, Raetz EA, et al. Impact of asparaginase discontinuation on outcome in childhood acute lymphoblastic leukemia: A report from the children’s oncology group. J Clin Oncol . 2020;38(17):1897-1905. doi:10.1200/JCO.19.03024
20. Gibson A, Hernandez C, Tejada FNH, Kawedia J, Rytting M, Cuglievan B. Asparaginase-Associated Pancreatitis in Pediatric Patients with Acute Lymphoblastic Leukemia: Current Perspectives. Paediatr Drugs . 2021;23(5):457-463. doi:10.1007/S40272-021-00463-1